CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

Jemperli accepted for priority review by US FDA

NDA FilingJemperliPositive
AI Analysis

Summary

Jemperli's supplemental BLA for dMMR/MSI-H stage II-III rectal cancer has been accepted for priority review by the US FDA, indicating potential expedited consideration of this indication expansion.

Outcome Details

Accepted for priority review

Importance:7/10
Sentiment:
0.70
FDA priority reviewsBLArectal cancerdMMR/MSI-Hregulatory approval

Read the original article

Published by PharmaTimes on August 31, 2026 9:59 AM

Read Original